As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to:www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global:
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Medicilon's chemistry department comprises synthetic chemistry services and medicinal chemistry services. Clients can work with us on a Fee for Service or Full-Time Equivalent basis.
In 2021, Medicilon established the International Discovery Service Unit (IDSU). The IDSU provides global pharmaceutical companies with high-quality, efficient and cost-effective chemistry synthesis design and production, as well as medicinal chemistry. The IDSU supports the discovery and delivery of clinical candidate compounds for global drug research and development.
The Pan-FGFR1-4 irreversible inhibitor RG002 tablets were approved for clinical use
The anti-tumor class I new drug SHP2 allosteric inhibitor RG001 tablet has been approved for clinical use
ABM Therapeutics presented Medicilon with a commemorative trophy for "our first candidate compound"